Source: Annual Congress 2003 - COPD vs AAT deficiency - similarities and differences
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Scheuch (Gemuenden, Germany). Targeting of drugs to the lung. Annual Congress 2003 - COPD vs AAT deficiency - similarities and differences

Member's Comments

No comment yet.

Related content which might interest you: Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015 Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Targeting Tryptophan metabolism pathway as a therapeutic strategy for non-small cell lung cancer Source: International Congress 2019 – Biology of lung cancer Year: 2019 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001 Innovative systemic lung cancer therapies Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Targeting repair in lung diseases Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005 Therapeutic approaches to lung aging Source: International Congress 2016 – The future is now: the challenge of ageing in respiratory medicine Year: 2016 Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Cardiovascular effects of innovative therapies in lung cancer Source: Eur Respir Monogr 2020; 88: 154-166 Year: 2020